CRAFITY score and nomogram predict the clinical efficacy of lenvatinib combined with immune checkpoint inhibitors in hepatocellular carcinoma

doi:10.3748/wjg.v31.i7.101672

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1599)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-3) series.

Item

Count

PDF

HTML

755

Figures (1-5)

158

Tables (1-3)

130

Sum=1078

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

230

Sum=321

Publishing Process of This Article

Item

Count

Browse

Download

Sum=125

Feb 21, 2025 (publication date) through Apr 21, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Feb 21, 2025; 31(7): 101672
Published online Feb 21, 2025. doi: 10.3748/wjg.v31.i7.101672

Full Size Figure Download Figure

Figure 3 Kaplan-Meier curves of progression-free survival and overall survival in patients with or without cirrhosis. A: Kaplan-Meier curves of progression-free survival; B: Kaplan-Meier curves of overall survival. PFS: Progression-free survival; OS: Overall survival.

Citation: Yin X, Deng N, Ding XY, Chen JL, Sun W. CRAFITY score and nomogram predict the clinical efficacy of lenvatinib combined with immune checkpoint inhibitors in hepatocellular carcinoma. World J Gastroenterol 2025; 31(7): 101672
URL: https://www.wjgnet.com/1007-9327/full/v31/i7/101672.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i7.101672